ENAH and hepatocellular carcinoma: The overexpression of MENA in hepatocellular carcinoma is associated with tumor differentiation and clinical staging; moreover, MENA is an independent prognostic biomarker for determining the disease-free survival (DFS) times of patients with hepatocellular carcinoma [18].